XNAS
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -1.29 | -1.39 | -7.75% | $0 | ❌ Miss | +0.00% | -14.77% | — |
| 2026-03-24 | Q4 2025 | -1.21 | -1.13 | +6.61% | $0 | ✅ Beat | +0.21% | -3.54% | +28.95% |
| 2025-11-13 |
| Q3 2025 |
| -1.16 |
| -0.99 |
| +14.66% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-11 | Q2 2025 | -1.09 | -1.05 | +3.67% | $0 | ✅ Beat | +0.00% | +0.49% | -8.60% |
| 2025-03-24 | Q4 2024 | — | -1.00 | — | $0 | — | +1.72% | -16.12% | +10.60% |
| 2024-11-18 | Q3 2024 | -1.22 | -1.19 | +2.46% | $0 | ✅ Beat | -13.07% | +12.59% | +9.94% |
| 2024-08-09 | Q2 2024 | -1.05 | -1.09 | -3.81% | $925,000 | ❌ Miss | -2.53% | -1.60% | -1.29% |
| 2024-05-10 | Q1 2024 | -1.13 | -1.00 | +11.50% | $0 | ✅ Beat | -5.72% | +2.49% | +14.92% |
Showing last 8 quarters.